SUMMARY Background
Non-alcoholic fatty liver disease (NAFLD) is associated with colorectal neoplasia. Yet, NAFLD ranges from simple steatosis to steatohepatitis with advanced fibrosis.
Aim
To investigate the risk of colorectal neoplasia according to the presence and severity of NAFLD.
Methods
A total of 26 540 asymptomatic adults who underwent same day first-time colonoscopy and abdominal ultrasonography as a health check-up programme were analysed. NAFLD was diagnosed by ultrasonography. Advanced colorectal neoplasia was defined as an invasive cancer or adenoma that was at least 10 mm in diameter, had high-grade dysplasia, or had villous histological characteristics or any combination thereof.
Results NAFLD patients had a higher prevalence of any colorectal neoplasia (38.0% vs. 28.9%) and advanced colorectal neoplasia (2.8% vs. 1.9%) compared to those without NAFLD. In a multivariable model adjusted for age, sex, smoking, alcohol, body mass index, first-degree family history of colorectal cancer, aspirin use and metabolic factors, the odd ratios comparing patients with NAFLD to those without were 1.10 [95% confidence interval (CI): 1.03-1.17] for any colorectal neoplasia and 1.21 (95% CI: 0.99-1.47) for advanced colorectal neoplasia. When NAFLD patients were further stratified according to the non-invasive parameters of liver disease severity, the risk of any colorectal neoplasia or advanced colorectal neoplasia was higher for those with severe liver diseases than those with mild liver diseases.
Conclusions
The presence and severity of NAFLD were closely associated with any colorectal neoplasia and advanced colorectal neoplasia, suggesting that clinicians should be aware of the increased risk of colorectal neoplasia in patients with NAFLD. 
INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the fourth leading cause of cancer deaths worldwide. 1 The recently updated US Preventive Services Task Force concluded that screening for CRC in average risk, asymptomatic adults aged 50-75 years is of substantial net benefit. 2 However, some populations are at increased risk for CRC, and there is a need for a more tailored approach to CRC screening. For example, patients with a family history of CRC are at increased risk for CRC, and recommended to start for CRC screening at a younger age and at a more frequent interval. 3 Identifying the risks of colorectal neoplasia can help inform screening participants and facilitate their screening choice. 4 Non-alcoholic fatty liver disease (NAFLD), characterised by accumulation of fat in the liver, is a rapidly increasing chronic liver disease. 5 The primary liver pathology in NAFLD affects hepatic structure and function, and causes liver cirrhosis, liver failure and hepatocellular carcinoma, but its clinical burden of NAFLD is not confined to the liver. 6 NAFLD is associated with an increased risk of type 2 diabetes mellitus, cardiovascular disease, and chronic kidney diseases 7 and cardiovascular disease is the leading cause of death in NAFLD patients. 8 Notably, cancer is the second highest cause of death followed by liver disease in the third place for NAFLD patients. 8 Recent studies have suggested that NAFLD may be a new, and added risk factor for extra-hepatic cancers, particularly CRC. 9 Possible mechanisms for the link between NAFLD and CRC include insulin resistance and obesity. [10] [11] [12] To date, several studies, including two meta-analyses, showed that NAFLD is a risk factor for colorectal neoplasia. [13] [14] [15] [16] [17] [18] However, NAFLD encompasses a wide spectrum of liver diseases ranging from simple steatosis to steatohepatitis with advanced fibrosis. 8 The literature on the association between severity of NAFLD and colorectal neoplasia is limited and inconsistent. 19, 20 The present study was designed to determine the association between NAFLD and colorectal neoplasia according to the severity of NAFLD in a large sample of asymptomatic adults undergoing first-time colonoscopy.
METHODS

Study design, setting, participants
This is a retrospective cross-sectional analysis that assessed the association between NAFLD and colorectal neoplasia. The study population was comprised of adult All colonoscopies were performed by board-certified endoscopists after bowel preparation with polyethylene glycol solutions. A complete examination was defined as one that reached the caecum, with a picture of the ileocecal valve obtained following adequate bowel preparation. All polypoid lesions were biopsied or removed with records of the location, size, number and appearance. Abdominal US was performed using LogiQ E9 (GE Healthcare, Milwaukee, WI, USA), iU22 xMatrix (Philips Medical Systems, Cleveland, OH, USA) or ACUSON Sequoia 512 equipment (Siemens, Issaquah, WA, USA) by experienced radiologists. Images were captured in a standard fashion with the patient in a supine position with the right arm raised above the head.
Study variables
The primary outcome variable was colorectal neoplasia, diagnosed during the colonoscopy exam. All of the colorectal neoplasia were histologically evaluated and classified according to the World Health Organization standards. 21 Advanced colorectal neoplasia was defined as an invasive cancer or adenoma that was at least 10 mm in diameter, had high-grade dysplasia, villous or tubulovillous histological characteristics, or any combination thereof. The exposure was the presence and severity of NAFLD. NAFLD was diagnosed with abdominal US. Fatty liver was assessed based on standard criteria, including parenchymal brightness, liver-to-kidney contrast, deep beam attenuation and bright vessel walls during abdominal US.
22, 23
Since we had excluded participants with excessive alcohol use (≥30 g/day for men and ≥20 g/day for women) as well as other identifiable causes of chronic liver disease as described in the exclusion criteria, fatty liver was considered NAFLD. Patients with NAFLD were further stratified according to the aspartate aminotransferase (AST) to platelet ratio index (APRI), fibrosis-4 score and NAFLD fibrosis score. The APRI was calculated by this calculation formula [(AST/normal upper limit AST)/platelet count] 9 100. 24 The fibrosis -4 score was calculated as age
. 25 NAFLD fibrosis score was calculated according to the published formula, which was À1.675 + 0.037 9 age (years) + 0.094 9 body mass index (BMI) (kg/m 2 ) + 1.13 9 impaired fasting glucose/ diabetes (yes = 1, no = 0) + 0.99 9 AST/ALT ratio À 0.013 9 platelet (910 9 /L) À 0.66 9 albumin (g/dL).
26
NAFLD fibrosis score is a validated tool used to assess NAFLD severity, and at a cutoff point of À1.455, it can exclude advanced fibrosis with high accuracy. A low APRI score (<0.5) and a low fibrosis-4 score (<1.45) are also strong predictors of the absence of liver fibrosis.
For the potential confounders, we collected data for age, sex, smoking, alcohol, BMI, first-degree family history of CRC, aspirin use, fasting blood glucose, use of diabetic medication, total cholesterol, triglyceride, use of dyslipidemic medication, systolic blood pressure and use of anti-hypertensive medication. Smoking status was categorised into never, former, current smoker or missing. Alcohol consumption was categorised into none or modest (<30 g/day in men and <20 g/day in women). BMI was calculated as weight in kilograms divided by height in meters squared.
Statistical analysis
The difference in the variables between patients with any colorectal neoplasia or advanced colorectal neoplasia and those without colorectal neoplasia was tested using Chisquare, t-test or Mann-Whitney U-test, as appropriate. The association between NAFLD and colorectal neoplasia was assessed using logistic regression analysis. We Exclusions (n = 12 158)
• History of liver cirrhosis (n = 515)
• Positive hepatitis B surface antigen (n = 1652)
• Positive anti-hepatitis C virus antibody (n = 335)
• Excessive alcohol drinking ≥30 g/day in men or 20 g/day in women (n = 10 309)
Eligible sample (n = 29 885)
• ≥18 years old who underwent colonoscopy and abdominal ultrasonography on the same day and without a history of chronic liver disease or heavy alcohol drinker Exclusions (n = 3345)
• Missing values: alcohol (n = 3133), body mass index (n = 16), systolic blood pressure (n = 19), fasting blood glucose (n = 3), lipid profiles (n = 261), NAFLD fibrosis score (n = 22), alanine aminotransferase (n = 7), aspartate aminotransferase (n = 3)
Final study sample (n = 26 540)
NAFLD, non-alcoholic fatty liver disease.
Aliment Pharmacol Ther 2017; 45: 345-353used three models with increasing levels of adjustment to account for potential confounding factors. Model 1 was adjusted for age and sex. Model 2 was further adjusted for smoking, alcohol, BMI, first-degree family history of CRC, and aspirin use. Model 3 was additionally adjusted for fasting blood glucose, use of diabetic medication, total cholesterol, triglyceride, use of dyslipidemic medication, systolic blood pressure, and antihypertensive medication, to account for possible mediation of the association between NAFLD and colorectal neoplasia by metabolic factors. All reported P values were two-sided and the significance level was set at 0.05.
RESULTS
Baseline characteristics of study participants
Among the 26 540 participants, the prevalence of any colorectal neoplasia and advanced colorectal neoplasia were 32.1% (8529) and 2.2% (588) respectively. Table 2 shows the baseline characteristics according to colorectal neoplasia status. The baseline characteristics were significantly different according to the colorectal neoplasia status. Patients with any colorectal neoplasia or advanced colorectal neoplasia were older, more likely to be male, had higher BMI, more smokers, fewer individuals with modest alcohol use, more individuals with first-degree family history of CRC and more metabolic risk factors compared to those without colorectal neoplasia. Serum ALT and gamma glutamyl transferase (GGT) levels were higher in-patients with colorectal neoplasia.
The association between the presence of NAFLD and colorectal neoplasia When evaluated by NAFLD status, NAFLD patients had higher prevalence of any colorectal neoplasia (38.0% vs. 28.9%, P < 0.001) and advanced colorectal neoplasia (2.8% vs. 1.9%, P < 0.001) than individuals without NAFLD (Table 3) . Table 4 shows the risks of any colorectal neoplasia and advanced colorectal neoplasia according to the presence of NAFLD. Significant association was found between NAFLD and any colorectal neoplasia. The association between NAFLD and any colorectal neoplasia persisted even after adjustments for potential confounders and metabolic parameters. These findings were the same for advanced colorectal neoplasia, although the association was attenuated and showed marginal association in model 3.
The association between the severity of NAFLD and colorectal neoplasia The risks of any colorectal neoplasia and advanced colorectal neoplasia were different according to the severity of NAFLD. When NAFLD patients were further stratified according to the non-invasive parameters of liver disease severities (APRI, fibrosis-4 score, and NAFLD fibrosis score, the prevalence of any colorectal neoplasia was higher for those with severe liver disease compared to those with mild liver disease. The prevalence of advanced colorectal neoplasia was higher for those with severe liver disease as well (Table 3) . When compared to individuals without NAFLD, the risks of any colorectal neoplasia and advanced colorectal neoplasia were significantly higher for NAFLD patients with severe liver disease in most cases, but not for those with mild liver disease (Table 5) .
When compared to NAFLD patients with mild liver disease, the ORs for any colorectal neoplasia and advanced colorectal neoplasia were higher for those with severe liver disease in most cases (Table 5) .
DISCUSSION
In this large cross-sectional study of asymptomatic men and women undergoing first-time screening colonoscopies, we found a significant association between the NAFLD and colorectal neoplasia. The magnitude of association was stronger for advanced colorectal neoplasia. The association was independent of traditional risk factors for CRC, including metabolic mediators. Furthermore, we found that the risk of any colorectal neoplasia or advanced colorectal neoplasia was higher for those with severe form liver diseases compared to mild form liver diseases. All these findings indicate that NAFLD and its severity are closely associated with the risk of colorectal neoplasia independent of traditional risk factors. Close attention for the increased risk for any colorectal neoplasia and advanced colorectal neoplasia is needed for NAFLD patients. Several previous studies showed that NAFLD is a risk factor for colorectal neoplasia. [13] [14] [15] [16] [17] [18] This study further supports that NAFLD is a significant factor for the colorectal neoplasia. In addition, we showed that NAFLD severity is linked to the risk of colorectal neoplasia. To our knowledge, there have been only two studies that assessed the association between NAFLD and colorectal neoplasia according to NAFLD severity. Wong et al. recruited subjects aged 40-70 years from community residents (n = 181) and biopsy proven NAFLD patients 
<0.001
NAFLD, non-alcoholic fatty liver disease; APRI, Aspartate aminotransferase to platelet ratio index.
* Adjusted for age, sex, smoking, alcohol, BMI, first-degree family history of CRC, aspirin use, fasting blood glucose, use of antidiabetic medication, total cholesterol, triglyceride, use of anti-dyslipidemic medication, systolic blood pressure, and use of antihypertensive medication. † For the fibrosis-4 score the multivariable model was not adjusted for age.
(n = 199). 20 They found that non-alcoholic steatohepatitis (NASH) is associated with a high prevalence of colorectal adenomas and advanced neoplasm, but not with simple steatosis. 15 In that study, the sample size was small. Moreover, NASH has to be diagnosed by a liver biopsy, 8 but liver biopsy is an invasive procedure with potential complications and is indicated for selected patients with NAFLD. 6, 8 Therefore, high selection bias is a concern, and the applicability is very limited for most NAFLD patients who lack histological information. Lee et al. studied 44 220 participants for the association between NAFLD severity and colorectal neoplasia by US grading. 19 They found that OR for colorectal neoplasia increases with an increase in NAFLD severity, but the association was not statistically significant in the multivariable model, and there was also no association between NAFLD severity and advanced colorectal neoplasia. 19 Abdominal US is the preferred first-line diagnostic procedure for imaging of NAFLD. 8 However, it can lead to an incorrect diagnosis of NAFLD in 10-30% of cases and cannot differentiate simple steatosis from steatohepatitis. 27, 28 Inter-observer and intra-observer variation is a great concern in assessing fatty liver severity by US, 29 and thus, grading fatty liver severity with US is not recommended by International guidelines. 6, 8 In the present study, we have tested several non-invasive parameters for liver disease severity including APRI, fibrosis-4 and NAFLD fibrosis score. In a systemic review with meta-analysis, these non-invasive tests were accurate in excluding advanced fibrosis in NAFLD patients. 30 Among these parameters, NAFLD fibrosis score has been widely validated in ethnically different NAFLD populations, with consistent results. 8, 26, 31 We were able to observe a trend of increasing ORs for any colorectal neoplasia and advanced colorectal neoplasia for those with severe liver disease. Recently, the European Association for the Study of the Liver recommended assessing serum fibrosis markers for those with evidence of hepatic steatosis. 8 Our data support this approach, as it could identify individuals at increased risk of complications (colorectal neoplasia) among NAFLD patients. In this study, the association between colorectal neoplasia and NAFLD was independent after adjusting for traditional risk factors including metabolic parameters (Table 4) . When NAFLD patients were stratified according to liver disease severity, the association between any or advanced colorectal neoplasia and NAFLD for patients with severe liver disease was robust after adjustment (Table 5) . However, for those with mild liver disease, the association was not obvious. NAFLD is considered as a hepatic manifestation of metabolic syndrome, 32, 33 and shares common risk factors for colorectal neoplasia including impaired glucose tolerance, dyslipidemia and central obesity. [10] [11] [12] One possible mechanism explaining the increased risk of colorectal neoplasia in NAFLD patients with advanced fibrosis is a pro-inflammatory and insulin resistant condition that elevates serum insulin and insulin-like growth factor, which in turn, may promote growth and anti-apoptosis of colorectal neoplasia. 20, 34 Some studies suggested that tumour necrosis factor-alpha, interleukin-6, adiponectin, leptin and other pro-inflammatory cytokines play a role in the development of colorectal neoplasia, [35] [36] [37] which can be altered in NASH as well. NASH may contribute to the development of colorectal neoplasia independent of traditional risk factors, while individuals with simple steatosis shows a higher risk of colorectal neoplasia by just sharing common risk factors for colorectal neoplasia. This study has some limitations that need to be considered in the interpretation. This study is comprised of health check-up participants who are likely to be highly motivated for their health by any reasons. They might not be representative of general population with average risk. In addition, South Koreans show disparities in prevalence, location and shape characteristics of colorectal neoplasia compared to Westerners. 38 Higher prevalence of adenoma has been reported for Black people, Hispanics than in White people. 39 Therefore, generalisability of this study to community and to other ethnicities needs to be demonstrated. Nevertheless, studies performed in Austria and Italy also showed an increased risk of colorectal neoplasia in NAFLD patients. 13, 16 Although colorectal neoplasia screening strategies need to be customised population by population, these findings suggest that NAFLD patients warrant close attention for increased risk of colorectal neoplasia regardless of ethnicity. The fatty liver was diagnosed with US, which has inter-and intra-observer variability. 29 Because of the long study duration, different radiologists were involved in performing abdominal US. Study personnel collecting the data, however, were unaware of the study aims, and measurement errors in liver US testing were independent and nondifferential. Different colonoscopists were also involved in performing colonoscopies, which was independent and nondifferential. Last, the cross-sectional design of the study cannot address causal relationships. Prospective association studies are needed to enhance our understanding. However, our study has several strengths, including the large sample size, inclusion of first-time colonoscopies, the availability of data on multiple metabolic risk factors, and the use of high quality clinical and laboratory measurements, which added to the strength of our findings.
In conclusion, we demonstrated that NAFLD and its severity are closely associated with the risk of any colorectal neoplasia and advanced colorectal neoplasia. The association was independent of traditional risk factors, especially for those with severe liver disease. Thus, clinicians should be aware of the increased risk of colorectal neoplasia in NAFLD patients, especially for those with severe liver disease. NASH resolution can improve dyslipidemia. 40 Regression of NAFLD is associated with reduced risk of developing carotid atherosclerosis. 41 Likewise, treatment of NAFLD may reduce the risk of colorectal neoplasia, which warrants further investigation.
